Business Wire

CA-ANDERSEN-GLOBAL

Del
Andersen Global udvider rækkevidde i London

Andersen Global fortsætter sin udvidelse i Storbritannien, idet Miles Dean, Zoe Wyatt og deres team slutter sig til Andersen Tax LLP-teamet i Storbritannien. Denne tilføjelse giver yderligere dybde til koncernen i London og forbedrer teamets evne til at arbejde sammen med kunder på en helhedsorienteret måde og yde uovertruffen og effektiv service. Andersen Global er repræsenteret fem steder i Storbritannien igennem sine medlems- og samarbejdsfirmaer.

Miles og Zoe har tidligere arbejdet for Milestone, som blev grundlagt af Miles Dean i 2008, og Zoe Wyatt blev partner i 2015. Som en del af Andersen Tax LLP vil disse partnere fortsat levere en bred vifte af internationale skattetjenester til virksomheder og private kunder, investeringsfonde og ejendomsinvestorer og -udviklere. Milestone underskrev en samarbejdsaftale med Andersen Global i 2018, og den positive indvirkning af dette forhold har ført til, at Miles, Zoe og deres team nu slutter sig til Andersen Global-medlemsfirmaet i Storbritannien.

“Det var enormt vigtigt for os at sikre, at vi er i stand til at yde det bedste for vores kunder. Vi ser virkelig frem til at fortsætte med at levere effektiv service og fordelen ved ekspertise fra de bedste rundt omkring i verden som en del af Andersen Global-familien,” sagde Miles Dean, grundlæggende partner hos Milestone og nu partner hos Andersen Tax LLP. “Jeg sætter pris på ​​at samarbejde med ligesindede partnere over hele kloden, og vores tid med Andersen Global, både som et samarbejdsfirma og nu som en del af det britiske medlemsfirma, har vist en fælles forpligtelse til at levere service af høj kvalitet.”

“At have Miles og Zoe som partnere i vores team er en naturlig udvikling, da vi har arbejdet tæt sammen med dem i mere end to år. Som en del af Andersen Tax LLP vil teamets komplementære ekspertise og erfaring give vores bredere koncern et markant løft på det dynamiske britiske marked, idet vi udvider vores rækkevidde i hele landet og globalt,” sagde George McCracken, administrerende direktør for Andersen Tax LLP.

“Miles, Zoe og deres team giver den slags unikke ekspertise og dedikation, der uden tvivl skiller sig ud fra resten. Teamet er indbegrebet af de egenskaber, som vi værdsætter hos Andersen, såsom gennemsigtighed, uovertruffen service og ledelse,” sagde Mark Vorsatz, bestyrelsesformand for Andersen Global og administrerende direktør for Andersen. “Idet vi fortsætter med at tilføje og udvide vores evner for kunder i Storbritannien, bygger vi videre på det eksisterende fundament i regionen og viser vores ildhu for at tilbyde effektive services over hele kloden.”

Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, der består af skatte- og juraeksperter fra hele verden. Andersen Global blev etableret af det amerikanske medlemsfirma Andersen Tax LLC i 2013 og har nu over 4.500 eksperter verden over og er repræsenteret mere end 149 steder igennem medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release

Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release

FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release

The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie

Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release

Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye